When
November 18, 2024
5:00 pm - 7:00 pm ET
Where
Organizer
Featured Speakers
Noopur Raje, MD
Director, Center for Multiple Myeloma, Massachusetts General Hospital
Dr. Noopur Raje is a Professor of medicine at Harvard Medical School, the director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, and the inaugural incumbent of the Rita Kelley Endowed Chair in Oncology at Massachusetts General Hospital. She is a translational researcher with a primary research focus on understanding the biology of myeloma and developing novel therapeutic strategies for the treatment of myeloma. She is specifically interested in bone biology of myeloma with a focus on the microenvironment and strategies to manipulate this niche. Dr. Raje trained in internal medicine at Massachusetts General Hospital and completed a fellowship in hematology and medical oncology at the Dana-Farber Cancer Institute in Boston.
Timothy Graubert, MD
Director, Hematologic Malignancy Program, Massachusetts General Hospital
Dr. Graubert is Professor of Medicine at Harvard Medical School and Director of the Hematologic Malignancy Program at the Massachusetts General Hospital (MGH) Cancer Center where he holds the Jon and JoAnn Hagler Chair in Oncology. Dr. Graubert is a physician-scientist with a laboratory-based research focus on the genetics of myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). His group has used new technologies to identify genetic alterations in patients with MDS and AML, then created animal models to study their mechanism of action and susceptibility to novel therapies. In addition to his research, Dr. Graubert oversees faculty recruitment and development for the Hematologic Malignancy Program and provides clinical care in the Center for Leukemia. He co-leads the Dana-Farber/Harvard Cancer Consortium Leukemia Program, is an Associate Member of the Broad Institute, and serves on scientific review panels for The Leukemia & Lymphoma Society, the American Society of Hematology, the National Institutes of Health, and Genome Canada.
David P. Ryan, MD
Physician-in-chief, Mass General Brigham
Chief, Hematology/Oncology
Clinical Director, Mass General Cancer Center
David Ryan, MD is the Shelby Memorial Professor of Medicine in the Field of Cancer Therapeutics at Harvard Medical School. He became chief of the Division of Hematology/Oncology at Mass General in October 2012. He is the clinical director of Mass General Cancer Center, and co-associate director for clinical science for the Dana-Farber/Harvard Cancer Center.
Dr. Ryan is an authority on the treatment of gastrointestinal cancers as well as the design and conduct of Phase I and II clinical trials for patients with those cancers. His expertise has been recognized by membership in leading national committees, including clinical task forces for the National Cancer Institute and the National Comprehensive Cancer Center Network.
Dr. Ryan received his hematology and oncology training through the combined Massachusetts General Hospital/Dana-Farber Cancer Institute fellowship program in 1996. He graduated in Medicine from Columbia College of Physicians and Surgeons in New York in 1992, and remained there for his internship and medical residency. He is a member of the American Association for Cancer Research (AACR) and American Society of Clinical Oncology (ASCO). Dr. Ryan sits on the editorial board of Clinical Cancer Research and The Oncologist. He is the author of more than 100 peer-reviewed manuscripts and a co-author of Living with Cancer.